文献速递免疫规划

重组蛋白新冠疫苗经肌内和黏膜途径接种在非人灵长类中的免疫原性及对奥密克戎BA.5的保护效果研究

Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
PubMed 文献 · Vaccine · 2024-01-22

本研究在小鼠和恒河猴中比较了Advax佐剂单价与二价重组刺突蛋白疫苗经肌内、肺内或口服途径接种的免疫原性。23只恒河猴分5组,经异源奥密克戎BA.5攻击后评估抗体与病毒载量。结果显示武汉+Mu二价疫苗诱导最广谱交叉中和抗体,肌内3剂和肌内2剂加口服2剂保护最佳,攻击后第2、4、7天肺部病毒载量较未免疫对照组降低。

要点

  • 武汉+Mu二价疫苗诱导最广谱交叉中和抗体应答。
  • 攻击前血清中检测不到针对BA.5的中和抗体。
  • 肌内3剂和肌内2剂加口服2剂保护最佳,肺部病毒载量降低。

核心结论

  • Advax佐剂单价或二价重组刺突蛋白疫苗经胃肠外和/或黏膜途径接种可针对异源BA.5攻击提供保护,尽管攻击前血清中无BA.5中和抗体。
  • 作者认为,使用口服Advax佐剂蛋白加强针以提供针对较新SARS-CoV-2变异株广谱保护的可能性值得进一步研究。

研究设计与样本

  • 先在小鼠中比较含多种刺突蛋白变异株的单价与二价疫苗的免疫原性。
  • 随后将23只恒河猴分为5组,经不同途径接种COVID-19疫苗。
  • 评估临床体征、局部接种部位反应、体重、摄食量、血清、肺泡灌洗液、鼻和口腔抗体水平,以及鼻和肺泡灌洗液病毒载量,并进行异源奥密克戎BA.5病毒攻击。

主要发现

  • 武汉+Mu二价疫苗诱导最广谱的交叉中和抗体应答。
  • 获得了针对武汉、Delta和Lambda变异株的强效血清中和抗体,但攻击前检测不到BA.5中和抗体。
  • 总体而言,肌内3剂和肌内2剂加口服2剂疫苗保护最佳,第2、4、7天肺部病毒载量较未免疫对照组降低。

局限性

  • 原文为初步研究(pilot study)。
  • 作者指出,使用口服Advax佐剂蛋白加强针以提供针对较新SARS-CoV-2变异株广谱保护的可能性值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With SARS-CoV-2 continuing to evolve, there is a need to adapt COVID-19 vaccines to enhance mucosal immunity and better address immune-evasive variants. This pilot study was performed in mice and rhesus macaques to compare Advax-adjuvanted monovalent and bivalent recombinant spike protein vaccines, including when delivered via a combination of intramuscular (IM) and intrapulmonary (IPM) or oral routes. METHODS: Mice were first used to compare the immunogenicity of monovalent and bivalent vaccines containing a variety of spike protein variants. Then, rhesus macaques (n = 23) were divided into 5 groups to receive COVID-19 vaccines via different routes. Clinical signs, local vaccination site reactions, body weight, food consumption, serum, alveolar lavage, nasal and oral antibody levels, and nasal and alveolar lavage virus loads were assessed in response to a heterologous Omicron BA.5 virus challenge. RESULTS: The Wuhan + Mu bivalent vaccine gave the most broadly cross-neutralizing antibody responses. Robust serum neutralizing antibodies against Wuhan, Delta and Lambda variants were obtained, but BA.5 neutralizing antibodies were not detectable pre-challenge. Overall, the IM x3 and the IM x2 plus oral x2 vaccines delivered the best protection, with reduced lung virus load versus unimmunized controls across Days 2, 4 and 7. CONCLUSIONS: Advax-adjuvanted monovalent or bivalent recombinant spike protein vaccines given via parenteral and/or mucosal routes protected against a heterologous BA.5 challenge, despite absent serum BA.5 neutralizing antibody, pre-challenge. The possibility of using an oral Advax-adjuvanted protein booster to provide broad protection against newer SARS-CoV-2 variants warrants further investigation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pal R, Ferrari MG, Honda-Okubo Y, et al. Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates. Vaccine. 2024. PMID: 38262808. doi:10.1016/j.vaccine.2024.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。